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Eighteen human histone deacetylases (HDACs) have
been identified, and according to their sequence simi-
larity to yeast homologs, these enzymes are grouped
into distinct classes. Within class II, HDAC4, HDAC5,
HDAC7, and HDAC9 share similar domain organization
both within the N-terminal extension and the C-termi-
nal catalytic domain, thus forming a subclass known as
class IIa. These HDACs function as signal-responsive
transcriptional corepressors. To gain further insight
into their function and regulation, we utilized an N-
terminal fragment of HDAC4 as bait in yeast two-hybrid
screens, which uncovered myocyte enhancer factor 2C,
14-3-3, and ankyrin repeat family A protein (ANKRA).
ANKRA is a poorly characterized protein with an
ankyrin repeat domain similar to RFXANK, a subunit of
the trimeric transcription factor RFX. Mutations on
genes of the RFX subunits and the coactivator CIITA are
responsible for the bare lymphocyte syndrome, an im-
munodeficiency disorder attributed to the lack of major
histocompatibility complex class II (MHCII) antigens.
Through its ankyrin repeat domain, RFXANK interacted
with HDAC4. Two RFXANK-binding sites were found on
HDAC4 with one located within residues 118–279 and
another within residues 448–666. Interestingly, this
deacetylase also interacted with CIITA. Consistent with
the physical interaction with RFXANK and CIITA,
HDAC4 and homologs repressed MHCII expression.
These results identify ANKRA, RFXANK, and CIITA as
novel targets of class IIa HDACs and suggest that these
deacetylases play a role in regulating MHCII expression.
Lysine acetylation refers to the addition of an acetyl moiety
to the -amino group of a lysine residue. Intensive research in
the past decade has uncovered that this covalent modification
occurs in over 50 transcription factors and about 30 other
proteins that are not directly involved in transcriptional con-
trol (1–4). Because histones were considered to be major
cellular proteins modified by lysine acetylation, many of the
responsible enzymes were initially identified as histone acetyl-
transferases and histone deacetylases (HDACs).1 It is now
clear that some of them also modify other protein substrates.
Known mammalian HDACs belong to distinct classes (5–8).
Within class II, there are six members, HDAC4, -5, -6, -7, -9,
and -10, whose catalytic domains exhibit significant sequence
homology to yeast Hda1. According to sequence similarity,
these six mammalian HDACs are further grouped into two
subclasses: IIa (HDAC4, -5, -7, and -9) and IIb (HDAC6 and
-10). Although little is known about biological functions of
HDAC10, HDAC6 has been well characterized as a tubulin
deacetylase (9–14).
Through interacting with DNA-binding transcription fac-
tors, class IIa HDACs play important roles in transcriptional
regulation (6, 8, 15). They interact with myocyte enhancer
factor 2 (MEF2) to control transcription during muscle differ-
entiation, T cell apoptosis, and neuronal survival. They also
serve as transcriptional corepressors for BCL6 and Runx pro-
teins (16–18). These HDACs are subject to regulation by signal-
dependent nucleocytoplasmic trafficking (7, 15). Protein ki-
nases, such as calcium/calmodulin-dependent kinase and
protein kinase D (also known as protein kinase C ), phospho-
rylate class IIa HDACs and promote their 14-3-3 binding and
cytoplasmic localization, thereby sequestering them away from
their nuclear targets (19–27). Thus, these HDACs are signal-
responsive transcriptional corepressors. To further understand
their function and regulation, we sought to identify additional
partners via yeast two-hybrid screening. One of the proteins
uncovered is ankyrin repeat family A protein (ANKRA), which
is known to interact with the cytoplasmic tail of megalin and
possesses an ankyrin repeat domain with significant homology
to regulatory factor for the X1 box with ankyrin repeats (RFX-
ANK) (28). Although little is known about the function of
ANKRA, an important role in transcriptional regulation has
been well documented for RFXANK. Thus, a major focus of this
report is on the effects of HDAC4 on RFXANK function.
Also known as RFX-B, RFXANK is a subunit of the trimeric
transcription factor RFX isolated from major histocompatibil-
ity complex class II (MHCII)-deficient patients (29–31). RFX-
ANK associates with RFX5 and RFXAP to form regulatory
factor for the X1 box (RFX), a DNA-binding complex that in-
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teracts specifically with the conserved X1 box of MHCII pro-
moters. All three subunits are required for the optimal binding
to the X1 box. RFX interacts with the transcriptional coactiva-
tor class II transactivator (CIITA) and recruits it to the X1 box
for transcriptional activation (31, 32). Mutations on the genes
of these four trans-acting proteins (i.e. RFX5, RFXAP, RFX-
ANK, and CIITA) form the genetic basis for different comple-
mentation groups of the bare lymphocyte syndrome, an auto-
somal recessive immunodeficiency due to the lack of MHCII
expression (30, 32). CIITA expression is tightly regulated and
exhibits a cell-specific, IFN-inducible, and differentiation-spe-
cific pattern that roughly parallels the synthesis of MHCII
(30–32). By contrast, RFX subunits are more ubiquitous and
constitutively expressed, indicative of additional functions. In-
deed RFX also functions as a repressor for collagen transcrip-
tion (33). Here we show that class IIa HDACs interact with the
ankyrin repeats of RFXANK as well as with CIITA to repress
MHCII transcription, thus uncovering a novel and unexpected
role of these deacetylases in regulating IFN-inducible gene
expression.
EXPERIMENTAL PROCEDURES
Cell Culture—NIH3T3, 293, and HeLa cells were maintained in
Dulbecco’s modified Eagle’s medium (Invitrogen) containing 10% fetal
bovine serum, penicillin, and streptomycin. Sf9 cells were maintained
for baculovirus expression as described previously (34, 35).
Plasmid Constructs—Mammalian expression plasmids for epitope-
tagged HDAC4 proteins have been described previously (20, 36, 37),
whereas those for murine HDAC5, murine HDAC7, and human MEF2-
interacting transcription repressor (MITR) were kindly provided by S.
Khochbin (38), E. Seto (39, 40), and X. Zhou (41), respectively. The
coding sequences of human ANKRA and RFXANK were cloned into
pcDNA3.1 (Invitrogen). Green fluorescent protein (GFP) constructs
were constructed from pEGFP-C2 (BD Biosciences). The CIITA mam-
malian expression plasmid and the DRA-Luc luciferase reporter have
been described previously (42, 43).
Yeast Two-hybrid Screening—Matchmaker Gal4 Two-hybrid System
3 (BD Biosciences) was utilized. To minimize false positive clones, this
system uses four reporters (ADE2, HIS3, MEL1, and LacZ) under the
control of distinct Gal4 upstream activating sequences linked to differ-
ent minimal promoters. Coding sequences for HDAC4 fragments were
fused in-frame to the yeast Gal4 DNA-binding domain in the vector
pGBKT7 to generate potential bait plasmids, which were transformed
into the yeast strain AH109 and analyzed for protein expression by
Western blotting. One bait plasmid (Fig. 1A, residues 1–666) expressed
an expected product. The AH109 strain harboring this bait plasmid was
thus used to mate with the yeast strain Y187 pretransformed with a
human fetal brain cDNA library, constructed with the yeast Gal4 acti-
vation domain vector pACT2 (BD Biosciences, catalog number
HY4028AH). After mating, about 1.0  107 diploid yeast cells were
selected on plates with the dropout medium containing 5-bromo-4-
chloro-3-indolyl--D-galactopyranoside (X--Gal) but lacking adenine,
histidine, leucine, and tryptophan. This screen yielded about 800 blue
colonies, which were further tested for 3-aminotriazole resistance (12.5
and 50 mM). 14 clones displayed resistance at both concentrations.
Library plasmids were successfully recovered from 13 of them, and
cDNA inserts were subcloned for sequencing. For testing the interac-
tion specificity, liquid -galactosidase assays were performed according
to the manufacturer’s instructions (BD Biosciences). Galactosidase ac-
tivity was measured using Galacto-Light PlusTM (Tropix) as the sub-
strate. The chemiluminescence from activated Galacto-Light Plus was
measured on a Luminometer plate reader (Dynex).
Protein-Protein Interaction—For examining the interaction of
HDAC4 with ANKRA in vitro, FLAG-HDAC4 was expressed in SF9
cells as described previously (34) and immobilized on M2 agarose beads
(Sigma). ANKRA and deletion mutants were synthesized in vitro with
the TNT T7 coupled reticulocyte lysate system (Promega) in the pres-
ence of Redivue L-[35S]methionine (Amersham Biosciences). After rota-
tion for an hour at 4 °C, agarose beads were washed three times with
buffer B (20 mM Tris-HCl, pH 8.0, 10% glycerol, 0.15 M KCl, 5 mM
MgCl2, 0.1% Nonidet P-40, and protease inhibitors) and once with the
same buffer containing 0.5 M KCl and then boiled in an SDS sample
buffer prior to SDS-PAGE and autoradiography.
In addition, ANKRA and RFXANK were expressed Escherichia coli
as proteins fused to maltose-binding protein (MBP). MBP and the
fusion proteins were incubated with FLAG-HDAC4 immobilized on M2
agarose. After extensive washing, bound proteins were eluted for SDS-
PAGE and staining with Coomassie Blue.
To compare their interaction with HDAC4, RFXANK and deletion
mutants were expressed in E. coli as proteins fused to MBP and immo-
bilized on amylose-agarose. HDAC4 was synthesized in vitro with the
TNT T7 coupled reticulocyte lysate system (Promega) in the presence of
Redivue L-[35S]methionine (Amersham Biosciences). After rotation for
an hour at 4 °C, agarose beads were washed three times with buffer B
and once with the same buffer with 0.5 M KCl and then boiled in the
SDS sample buffer prior to SDS-PAGE, Coomassie staining, and auto-
radiography.
To analyze the interaction of HDAC4 with RFXANK in vivo, expres-
sion plasmids for FLAG-tagged HDAC4, deletion mutants, and other
class IIa HDACs were transfected into 293 cells along with HA-RFX-
ANK expression plasmid as specified. 10 g of plasmids was used to
transfect 5–10  105 cells (in a 10-cm dish) with 24 l of SuperFect
(Qiagen) or TransIT (Mirus) transfection reagent. 48 h after transfec-
tion, cells were washed twice with phosphate-buffered saline and col-
lected in 1 ml of buffer K (20 mM sodium phosphate, pH 7.0, 150 mM
NaCl, 30 mM sodium pyrophosphate, 0.1% Nonidet P-40, 5 mM EDTA,
10 mM NaF, 0.1 mM Na3VO4, and protease inhibitors). Cell extracts (0.5
ml) were prepared for affinity purification on 15 l of anti-FLAG M2
agarose (Sigma). After four washes with buffer K (0.3 ml each), bound
proteins were eluted with the same buffer containing 0.2 mg/ml FLAG
peptide (Sigma). Eluted proteins were subsequently resolved by 10%
SDS-PAGE and transferred to nitrocellulose membrane for Western
blotting analysis with anti-FLAG and anti-HA antibodies. Blots were
developed with Supersignal substrates (Pierce). Interaction of RFX5,
RFXAP, or CIITA with RFXANK in vivo was analyzed similarly.
Immunofluorescence Microscopy—Green fluorescence and indirect
immunofluorescence microscopic analyses were performed as described
previously (20, 37, 44) except that after incubation with secondary
antibody, cells were stained with 2.5 g/ml Hoechst 33258 (Sigma) for
60 s to locate nuclei.
Reporter Gene Assays—Reporter gene assays were performed as de-
scribed previously (35, 36).
Reverse Transcription-PCR—HeLa cells (1  106) were plated in
150-mm tissue culture plates and transfected 18 h later using FuGENE
6 (Roche Applied Science) according to the manufacturer’s instructions.
24 h post-transfection, cells were harvested, and cDNA was synthesized
as described previously (43, 45). Real time PCR was performed using
the ABI Prism 7900 sequence detection system (PerkinElmer Life Sci-
ences). The MHCII probe was labeled at the 5 end with the reporter dye
FAM and at 3 end with the quencher dye TAMRA. The 18 S rRNA
probe was labeled at the 5 end with the reporter dye TET and at the 3
end with the quencher dye TAMRA. Primer and probe sequences are as
follows: MHCII probe, 5-6 FAM-CTC CGA TCA CCA ATG TAC CTC
CAG A-TAMRA-3; sense primer, 5-AAG CCA ACC TGG AAA TCA-3;
antisense primer, 5-GGC TGT TCG TGA GCA CAG TT-3; and 18 S
rRNA probe, 5-6 FAM-CAA ATT ACC CAC TCC CGA CCC G-TAMRA-
3; sense primer, 5-GCT GCT GGC ACC AGA CTT-3; antisense
primer, 5-CGG CTA CCA CAT CCA AGG-3. Real time PCR analysis of
cDNA samples was conducted as described previously (45).
RESULTS
Identification of New Binding Partners of HDAC4—To gain
further insight into the function and regulation of class IIa
members, we performed yeast two-hybrid screens with an N-
terminal fragment of HDAC4 as bait (Fig. 1A). Because this
deacetylase is highly expressed in the brain, a human fetal
brain cDNA library was used. From the screen, 13 positive
clones were obtained. 10 of them expressed the right protein
products, including fragments of MEF2C (two clones), 14-3-3
(one clone), ANKRA (two clones), ATRX (one clone), REV3L
(catalytic subunit of DNA polymerase ; two clones) and
C19orf5 (chromosome 19 orf5, recently renamed MAP1S for
microtubule-associated protein 1S; two clones). 14-3-3 proteins
interact with HDAC4 in a phosphorylation-dependent manner
(19, 20), so there could be a yeast kinase phosphorylating
HDAC4 and promoting its association with 14-3-3. Because
MEF2C and 14-3-3 are known HDAC4 partners highly ex-
pressed in the brain, the screening was specific and efficient.
C1 and C11, two ANKRA fragments from the positive clones,
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overlap with each other (Fig. 1B). As shown in Fig. 1C, both
specifically activated -galactosidase expression, indicating
that the interaction is specific. To substantiate this, we per-
formed in vitro binding assays. FLAG-tagged HDAC4 was ex-
pressed in SF9 cells and immobilized on M2 agarose for binding
to C1 and C11 produced using an in vitro transcription and
translation system in the presence of L-[35S]methionine. Bound
proteins were resolved by SDS-PAGE and detected by autora-
diography. As shown in Fig. 1, D and E, HDAC4 interacted
with both fragments, supporting that HDAC4 binds directly
to ANKRA.
As expected, HDAC4 also specifically interacted with full-
length ANKRA (Fig. 1F, lanes 1–3). By contrast, its N-terminal
121 residues failed to associate with HDAC4 (lanes 4–6), indi-
cating that the ankyrin repeat domain is required for the
binding. To further characterize this association, we expressed
ANKRA as an MBP fusion protein and tested for binding to
FLAG-HDAC4 immobilized on M2 agarose. Bound proteins
were eluted and separated by SDS-PAGE for staining with
Coomassie Blue. As shown in Fig. 2A (lanes 1, 2, 4, 5, and 7 and
8), HDAC4 retained MBP-ANKRA but not MBP. Importantly,
the association was almost stoichiometric, suggesting that the
binding to ANKRA is strong.
HDAC4 Interaction with RFXANK—ANKRA was originally
identified in yeast two-hybrid screens where the cytoplasmic
tail of megalin was used as bait (28), but its function is barely
known. Ankyrin repeats are protein-protein interaction motifs
implicated in a wide range of biological processes (46). The
ankyrin repeat domain of ANKRA shows significant homology
to RFXANK (sequence identity, 60%; Fig. 2B) (28, 47). Be-
cause the ankyrin repeats of ANKRA appeared to mediate the
interaction with HDAC4 (Fig. 1), we tested whether this
deacetylase also binds to RFXANK. For this, RFXANK was
expressed as an MBP fusion protein in E. coli and tested for
binding to FLAG-HDAC4 expressed in SF9 cells and immobi-
lized on M2 agarose. Bound proteins were eluted, and after
separation by SDS-PAGE, they were detected by Coomassie
staining. As shown in Fig. 2A (lanes 3, 6, and 9), HDAC4
specifically interacted with RFXANK albeit less strongly than
with ANKRA.
We next analyzed the interaction using immobilized RFX-
ANK. For this, MBP-RFXANK was immobilized on amylose-
agarose and used for binding to HDAC4, synthesized, and
labeled in vitro with L-[35S]methionine. As shown in Fig. 2C
(lanes 1, 2, and 8), MBP-RFXANK but not MBP retained
HDAC4, providing further support for RFXANK interaction
with HDAC4. To map the region mediating this interaction, we
engineered truncation mutants of RFXANK by gradually re-
moving its ankyrin repeats from the C-terminal end (Fig. 2B).
These mutants were expressed in E. coli as MBP fusion pro-
teins, immobilized on amylose-agarose, and tested for binding
to labeled HDAC4. As shown in Fig. 2C (bottom), amounts of
the fusion proteins retained on the resin were similar. Trunca-
tion to residue 248, 213, or 180 had modest effects on HDAC4
binding (Fig. 2C, top, lanes 5–7), whereas further removal of
ankyrin repeat 2 exerted a more dramatic effect (lane 4). Trun-
mid or the empty vector expressing the Gal4 DNA-binding domain
(DBD) as indicated. As an additional control, the expression plasmid
pACT2 for the Gal4 activation domain (AD) was co-transformed with
the bait expression plasmid. Average values of -galactosidase activi-
ties in yeast extracts were determined and are shown with standard
deviations. RLU, relative light units. D–F, in vitro pull-down assays.
FLAG-HDAC4 was expressed in SF9 cells, immobilized on M2 agarose,
and incubated with [35S]methionine-labeled ANKRA proteins as indi-
cated. Bound proteins were eluted for SDS-PAGE and autoradiography.
Input lanes represent 20% of [35S]methionine-labeled proteins used for
binding assays. Plain SF9 extracts were used as mock controls.
FIG. 1. Interaction of ANKRA with HDAC4. A, schematic repre-
sentation of HDAC4. The deacetylase domain is depicted with a rectan-
gle. The MEF2-binding motif is drawn as a small box, and 14-3-3-
binding motifs are indicated with small boxes labeled with the letter “S”
(for serine). Also shown is an HDAC4 fragment (residues 1–666) used
as bait in yeast two-hybrid screens. B, schematic illustration of ANKRA
and fragments. C1 and C11 correspond to fragments encoded by two
clones isolated from the screens. C, liquid -galactosidase activity as-
says. Expression plasmids for C1 and C11 were transformed into Y187,
which was then mated with AH109 harboring the bait expression plas-
Deacetylase Association with ANKRA and RFXANK 29119
cation to residue 116 completely abolished the binding (lane 3).
Therefore, ankyrin repeats 1 and 2 are required for HDAC4
binding (Fig. 2, B and C).
Mapping of the RFXANK-binding Sites on HDAC4—To de-
lineate the region important for RFXANK binding, we utilized
a series of HDAC4 deletion mutants that has been described
previously (Fig. 3A) (20, 34, 37, 48). They were synthesized,
labeled in vitro with L-[35S]methionine, and used for binding to
MBP-RFXANK immobilized on amylose-agarose. Consistent
with the fact that the N-terminal fragment of HDAC4 was used
as bait in the two-hybrid screens (Fig. 1A), mutant 1–666 but
not 621–1084 interacted with RFXANK (Fig. 3B). As expected,
MBP-RFXANK retained full-length HDAC4 (Fig. 3C, lanes
1–3). Neither 208–1084 nor 315–1084 (lanes 4–9) was retained,
indicating that the N-terminal 207 residues are required for
the binding. To further define the binding site, deletion mu-
tants 1–326, 1–279, 1–266, and 1–208 were analyzed (Fig. 3A).
Although mutants 1–326 and 1–279 interacted strongly with
RFXANK, the binding to mutant 1–266 was weaker, and 1–208
showed no detectable binding (Fig. 3D), suggesting that resi-
dues 209–278 are also essential for the interaction. Immobi-
lized MBP-RFXANK efficiently retained mutant 118–326 but
not 315–666 (Fig. 3, E and F). Together, these results indicate
that a direct RFXANK-binding site resides within residues
118–279 of HDAC4.
To examine the binding in vivo, we performed co-immuno-
precipitation. Expression plasmids for FLAG-HDAC4 and HA-
RFXANK were transfected into HEK293 cells, and extracts
were prepared for immunoprecipitation on M2 agarose. Precip-
itated proteins were eluted and analyzed by Western blotting
with anti-FLAG and anti-HA antibodies. As shown in Fig. 3G
(lanes 1 and 7), RFXANK co-precipitated with HDAC4. In the
same assays, we also analyzed mutants 206–1084 and 315–
1084, which showed no RFXANK interaction in vitro (Fig. 3C).
Unexpectedly, both mutants co-precipitated RFXANK much
more efficiently than wild-type HDAC4 (Fig. 3G, lanes 1–3 and
7–9), suggesting that RFXANK binds indirectly to these two
mutants and the N-terminal 207 residues of HDAC4 inhibit
this binding. To delineate the inhibitory domain, we tested
mutants with smaller truncations. As shown in Fig. 3G (lanes
4, 5, 10 and 11), mutant 146–1084 co-precipitated RFXANK
slightly more efficiently than wild-type HDAC4, whereas 189–
1084 was almost as efficient as 206–1084 and 315–1084. In the
same assays, mutant 621–1084 did not retain RFXANK, so the
co-precipitation was specific. These results thus indicate that
residues 147–188 are critical for the inhibition and that an
indirect RFXANK-binding site resides within residues
315–620.
RFXANK associated with the N-terminal 279 residues of
HDAC4 in vitro (Fig. 3, C–F), so the indirect binding site did
not appear to overlap with the direct one. To substantiate this,
we analyzed mutants 1–666, 1–326, and 315–666. As shown in
Fig. 3H (lanes 1–3 and 5–7), 1–666 and 315–666 but not 1–326
co-precipitated RFXANK. Importantly, 315–666 was more ef-
ficient than 1–666. Moreover, mutant 488–666 was almost as
efficient as 315–666, indicating that the indirect binding site is
located within residues 488–666. These results also provide
further support for the conclusion that the N-terminal region of
HDAC4 dramatically inhibits the indirect binding. Because
mutant 1–326 interacted with RFXANK in vitro (Fig. 3D) but
not in vivo (Fig. 3H), RFXANK binding to residues 118–279
may be inhibited in cells. These results indicate that HDAC4
possesses two RFXANK-binding sites and further suggest that
the binding is regulated in vivo.
Interaction of Different Class IIa HDACs with ANKRA and
RFXANK—Because the two RFXANK-binding sites on HDAC4
are conserved among HDAC5, -7, and -9, we asked whether
these three HDACs interact with RFXANK and ANKRA. To
address this, in vitro binding assays were performed with
HDAC5 and HDAC7 labeled in vitro with L-[35S]methionine.
They were incubated with MBP-ANKRA and -RFXANK immo-
bilized on amylose-agarose. Bound proteins were eluted for
SDS-PAGE, Coomassie staining, and autoradiography. For
FIG. 2. Direct interaction of HDAC4 with ANKRA and RFX-
ANK. A, FLAG-HDAC4 was expressed in SF9 cells, immobilized on M2
agarose, and incubated with MBP, MBP-ANKRA, or MBP-RFXANK as
specified. Bound proteins were eluted for SDS-PAGE and Coomassie
staining. Inputs (lanes 1–3) represent 20% of MBP or MBP fusion
proteins used for binding assays. Bands corresponding to IgG heavy
chain (IgG H) that randomly came off from M2 agarose are indicated at
right. The MBP band on lane 1 is marked with an asterisk. B, schematic
illustration of RFXANK and truncation mutants. The ankyrin repeat
region (rectangles, with ankyrin repeats numbered) is homologous to
ANKRA (sequence identity, 60%). The HDAC4 binding ability of
RFXANK and truncation mutants is shown at right with plus and
minus representing positive and negative interactions, respectively. C,
in vitro MBP pull-down assays. MBP (lane 2) and MBP-RFXANK pro-
teins (lanes 3–8) were expressed in E. coli, immobilized on amylose-
agarose, and incubated with [35S]methionine-labeled HDAC4. Bound
proteins were eluted for SDS-PAGE, Coomassie staining (bottom), and
autoradiography (top). Input (lane 1) represents 20% of labeled HDAC4
used for each binding assay.
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comparison, labeled HDAC4 was also assessed in the same set
of experiments. As shown in Fig. 4A, like HDAC4, HDAC5
specifically interacted with ANKRA and less strongly with
RFXANK (lanes 1–8). HDAC7 was found to bind RFXANK and
ANKRA almost equally (lanes 9–12). We then compared RFX-
ANK binding affinity of class IIa HDACs by co-immunoprecipi-
tation. As shown in Fig. 4B, they co-precipitated RFXANK
rather similarly. Therefore, RFXANK and ANKRA are able to
interact with class IIa HDACs in vitro and in vivo.
Co-localization of RFXANK and ANKRA with Class IIa
HDACs—To examine the subcellular localization of these
ankyrin repeat proteins, we performed fluorescence micros-
copy. NIH3T3 cells were transfected with expression plasmids
for GFP-RFXANK and -ANKRA, and transfected cells were
examined for green fluorescence. Although GFP itself was pan-
cellular, GFP-ANKRA and -RFXANK were found both in the
nucleus and the cytoplasm with some nuclear enrichment (Fig.
5A). Consistent with previous reports (20, 37), HDAC4 was
predominantly cytoplasmic, HDAC5 was nuclear, and HDAC7
was pancellular or slightly enriched in the nucleus (Fig. 5B).
We then investigated whether RFXANK and ANKRA co-local-
ize with these three HDACs. For this, an expression plasmid
for GFP-RFXANK or -ANKRA was co-transfected into NIH3T3
cells with HA-tagged HDACs. As shown in Fig. 5, C and D,
expression of the HDACs caused some enrichment of RFXANK
and ANKRA in the nucleus. Moreover, the HDACs displayed
some co-localization with these ankyrin repeat proteins. In-
triguingly, HDAC4, but not HDAC5 or HDAC7, led to reloca-
FIG. 3. Mapping the RFXANK-bind-
ing sites on HDAC4. A, schematic rep-
resentation of HDAC4 and deletion mu-
tants. The domain organization of
HDAC4 is illustrated as in Fig. 1A. The
RFXANK binding ability of HDAC4 and
deletion mutants in vitro and in vivo is
indicated at right: , low affinity; ,
high affinity; , no detectable binding;
nd, not determined. B–F, in vitro MBP
pull-down assays. MBP and MBP-RFX-
ANK were expressed in E. coli, immobi-
lized on amylose-agarose, and incubated
with [35S]methionine-labeled HDAC4 and
mutants as specified. Bound proteins
were eluted for SDS-PAGE and autora-
diography. Input lanes represent 20% of
labeled proteins used for each binding as-
say. G and H, co-immunoprecipitation
(IP) assays. The expression plasmid for
HA-tagged RFXANK was co-transfected
into HEK293 cells with those for HDAC4
and deletion mutants (FLAG-tagged) as
indicated. Extracts were prepared for im-
munoprecipitation on M2 agarose, and
bound proteins were eluted with FLAG
peptide for Western blotting (WB) with
anti-FLAG and anti-HA antibodies. Ex-
pression of mutants 315–666 and 448–
666 was barely detectable in extracts.
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tion of GFP-RFXANK to nuclear dots in about 5–10% of trans-
fected cells (Fig. 5C). This effect was more dramatic with
ANKRA: in 40% cells, it formed dots in the nucleus (Fig. 5D).
Moreover, in some cells, HDAC4 co-localized with RFXANK or
ANKRA in the dots (Fig. 5, C and D). Although the nature of
the nuclear dots awaits further investigation, these results
provide further support for the interaction of RFXANK and
ANKRA with these HDACs in vivo.
Repression of MHCII Gene Expression by HDAC4—We next
assessed whether RFXANK recruits HDAC4 to repress tran-
scription. For this, RFXANK was expressed as a protein fused
to the Gal4 DNA-binding domain, and the ability to regulate
the transcriptional activity of the luciferase reporter Gal4-tk-
Luc in which the luciferase gene is under the control of a
thymidine kinase (tk) core promoter and six copies of the Gal4-
binding site (34) was analyzed. As shown in Fig. 6A, Gal4-
RFXANK activated the reporter activity (10-fold), whereas
HDAC4 inhibited the activity in a manner dependent on the
Gal4 fusion protein, suggesting that RFXANK enlists HDAC4
to repress transcription.
RFXANK is required for assembling the RFX complex, which
recognizes the X1 box of MHCII promoters and recruits the
coactivator CIITA to activate transcription (30, 31), so we in-
vestigated whether class IIa HDACs repress CIITA-mediated
activation of MHCII genes. This was first evaluated by tran-
sient transfection of NIH3T3 cells with a luciferase reporter
under the control of an HLA-DRA promoter fragment. This
reporter has been used to analyze the transcriptional regula-
tion by RFX and CIITA (43). As shown in Fig. 6B, HDAC4
repressed the reporter activity in a dose-dependent manner.
CIITA is not expressed in fibroblasts like NIH3T3. As shown
in Fig. 6C, expression of CIITA stimulated the DRA-Luc re-
porter activity (35-fold) in these cells. Exogenous RFXANK
and RFX5 had minimal effects on CIITA-mediated transacti-
vation (data not shown), suggesting that levels of RFX5 and
RFXANK are not limiting in NIH3T3. CIITA-dependent acti-
vation was inhibited by HDAC4 in a dose-dependent manner
(Fig. 6C). HDAC5 also exerted inhibitory effects (Fig. 6C).
Therefore, these HDACs are able to repress MHCII expression.
To investigate the physiological relevance, we assessed how
HDAC4 regulates the expression of endogenous MHCII. For
this, HeLa cells were transfected with the CIITA expression
plasmid in the presence or absence of the HDAC4 expression
plasmid. RNA was isolated for cDNA synthesis and real time
PCR to quantify MHCII mRNA. As shown in Fig. 7A, CIITA
stimulated the expression, whereas HDAC4 inhibited this
stimulation. To determine which region of HDAC4 was in-
volved, we analyzed two deletion mutants. Although mutant
621–1084 had minimal effects, mutant 1–666 blocked the ac-
tivation of MHCII expression by CIITA (Fig. 7A). Interestingly,
mutant 1–666 was slightly more potent than full-length
HDAC4 (Fig. 7A). This mutant harbors both RFXANK-binding
sites (Fig. 3). Moreover, it is exclusively nuclear and possesses
a potent repression domain (34, 37).
We next analyzed how HDAC4 affects IFN-inducible gene
expression. For this, HeLa cells were treated with IFN, and
MHCII mRNA was quantified as above. As reported previously
(43), IFN induced MHCII expression (Fig. 7B). HDAC4 and
mutant 1–666, but not 621–1084, inhibited the induction (Fig.
7B). IFN is known to activate MHCII transcription by induc-
ing CIITA expression (30, 32), so we analyzed effects of HDAC4
and mutants on CIITA mRNA levels. As shown in Fig. 7C,
HDAC4 and the mutants had minimal effects on CIITA expres-
sion, indicating that the inhibitory effects of HDAC4 and mu-
tant 1–666 on MHCII expression (Fig. 7B) are not due to
reduction of CIITA expression. Therefore, HDAC4 is able to
inhibit IFN-inducible expression of endogenous MHCII.
Interaction of HDAC4 and HDAC5 with CIITA—Because
class IIa HDACs interact with RFXANK and repress RFX-de-
pendent transcription, we wondered whether they also target
RFX5, RFXAP, and CIITA. Among these, we found that
HDAC4 and HDAC5 interacted with CIITA (Fig. 8A). More-
over, HDAC5 co-localized with CIITA (Fig. 8B). RFXANK in-
teracts with RFX5 and CIITA (49), so we investigated
whether HDAC4 interferes with the interactions. For this,
co-immunoprecipitation was performed. As expected, RFX5
co-precipitated RFXANK (Fig. 8, C–E, lanes 1). Exogenous
HDAC4 slightly affected the co-precipitation (Fig. 8D, com-
pare lanes 1 and 2). Under the conditions used, RFXAP did
not co-precipitate RFXANK (Fig. 8, C–E, lanes 3 and 4). Like
RFX5, CIITA co-precipitated RFXANK (Fig. 8, C–E, lanes 5).
Expression of HDAC4 affected the co-precipitation (compare
lanes 5 and 6). As described above (Fig. 8A), CIITA also
co-precipitated HDAC4 (Fig. 8, C–E, lanes 6). Importantly
the binding affinity of HDAC4 to CIITA was quite compara-
ble to that of RFXANK to CIITA (lanes 5 and 6). The biolog-
ical significance for the interaction between RFXANK and
CIITA has been well established (31, 32). These results thus
FIG. 4. Interaction of ANKRA and RFXANK with class IIa HDACs. A, in vitro MBP pull-down assays. MBP, MBP-ANKRA, and
MBP-RFXANK were expressed in E. coli, immobilized on amylose-agarose, and incubated with [35S]methionine-labeled HDAC4, -5, and -7 as
indicated. Bound proteins were eluted for SDS-PAGE and autoradiography. Input lanes represent 20% of labeled proteins used for binding assays.
B, co-immunoprecipitation (IP). The expression plasmid for HA-RFXANK was co-transfected into NIH3T3 cells with that for FLAG-tagged HDAC4,
-5, -7, or MEF2-interacting transcription repressor (MITR). The HDAC4 mutant 621–1084 was used as the negative control. Extracts were
prepared for immunoprecipitation on M2 agarose, and bound proteins were eluted with FLAG peptide for Western blotting (WB) with anti-FLAG
and anti-HA antibodies as indicated. Expression of HDAC7 (asterisk, lane 3) was barely detectable in extracts. In HEK293 cells, RFXANK also
co-precipitated with these HDACs (data not shown).
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FIG. 5. Subcellular localization of RFXANK, ANKRA, and class IIa HDACs. A, expression plasmids for GFP-ANKRA and GFP-RFXANK
were transfected into NIH3T3 cells. 24 h after transfection, cells were fixed and examined for green fluorescence. B, an expression plasmid for
HA-tagged HDAC4, -5 or -7 was transfected into NIH3T3 cells. 24 h after transfection, the cells were fixed and stained with anti-HA antibody for
indirect immunofluorescence microscopy. C and D, an expression plasmid for HA-tagged HDAC4, -5, or -7 was transfected into NIH3T3 cells along
with an expression plasmid for GFP-ANKRA or -RFXANK as indicated. 24 h after transfection, cells were fixed and stained with anti-HA antibody
to detect HDAC4, -5, or -7 by indirect immunofluorescence microscopy. Green fluorescence was used to locate GFP fusion proteins. Merged images
are also shown with yellow signals indicating co-localization. GFP itself showed no co-localization with the HDACs (data not shown).
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suggest that HDAC4 also targets CIITA and affects the as-
sembly of the RFX-CIITA enhanceosome.
DISCUSSION
ANKRA and RFXANK as Novel Partners of Class IIa
HDACs—Yeast two-hybrid screens with HDAC4 as bait (Fig.
1A) yielded two known interaction partners (MEF2C and 14-
3-3) and four novel ones (ANKRA, ATRX, REV3L, and micro-
tubule-associated protein 1S), suggesting that HDAC4 and its
homologs may also be involved in regulating cell processes
other than transcriptional regulation. The high sequence sim-
ilarity to RFXANK (28, 47) suggests a potential role of ANKRA
in transcriptional regulation. Consistent with this notion,
ANKRA interacted and displayed partial co-localization with
HDAC4 and other class IIa HDACs (Figs. 1, 2A, 4, and 5D) and
was able to enter the nucleus (Fig. 5, A and D). ANKRA has
been shown to interact with membrane-associated receptors
(28, 50), so an interesting possibility is that it acts as a signal-
ing adaptor to facilitate the communication between the
plasma membrane and the nucleus. This possibility needs to be
investigated further.
The ankyrin repeat domain of ANKRA appeared to be nec-
essary for HDAC4 interaction (Fig. 1, B–F). Similarly, the
ankyrin repeat domain of RFXANK interacted with HDAC4
(Fig. 2). RFXANK was originally isolated from MHCII-deficient
patients as one subunit of the trimeric transcription factor RFX
(51, 52) and contains four ankyrin repeats in its C-terminal
FIG. 6. Repression of CIITA-dependent transcription by
HDAC4 and HDAC5. A, the luciferase reporter Gal4-tk-Luc was
transfected into HEK293 cells along with a -galactosidase expres-
sion plasmid and a plasmid expressing RFXANK as a protein fused to
the Gal4 DNA-binding domain (residues 1–147). An HDAC4 expres-
sion plasmid was also co-transfected as indicated. The normalized
luciferase activity from the transfection without any effector plas-
mids was arbitrarily set to 1.0. Average values of at least three
independent experiments are shown with standard deviations. B, the
luciferase reporter DRA-Luc (0.4 g) was transfected into NIH3T3
cells with increasing amounts of the HDAC4 expression plasmid
(0.05–0.2 g). A cytomegalovirus -galactosidase reporter (0.05 g)
was included for normalization of transfection efficiency. C, assays
were performed as in B except that expression plasmids for CIITA
and HDAC5 were also included as indicated.
FIG. 7. Repression of MHCII expression by HDAC4. A, HDAC4
inhibits CIITA-dependent activation of MHCII expression. Real time
PCR analysis was performed to quantify MHCII mRNA. CIITA and
HDAC4 expression plasmids were transfected into HeLa cells as indi-
cated, and RNA was isolated 24 h post-transfection. Samples were
normalized to 18 S rRNA. B and C, HDAC4 represses IFN-inducible
expression of MHCII. Real time PCR analysis was performed to deter-
mine levels of MHCII (B) and CIITA (C) mRNA. Expression plasmids
for HDAC4 and mutants were transfected into HeLa cells followed by
24-h treatment with IFN (500 units/ml). For CIITA (C), mRNA tran-
scribed from promoter IV was measured (68).
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region (Fig. 2B). Ankyrin repeats are common sequence motifs,
and each repeat comprises 33 residues (46). Such motifs have
been found in cell cycle regulators, signaling modulators, tran-
scription factors, cytoskeletal organizers, and toxins. One ma-
jor function of these motifs is to mediate protein-protein inter-
action. Ankyrin repeats of RFXANK provide an interaction
platform to assemble the RFX complex (53, 54). Repeats 2–4
mediate the binding of RFXANK to CIITA, and repeat 2 is
essential for the binding (49). Our results indicate that the
ankyrin repeat domains of RFXANK and ANKRA are required
for HDAC4 association (Figs. 1–2). Further mapping revealed
that repeats 1 and 2 of RFXANK are important for the binding
(Fig. 2, B and C), suggesting that the binding site for HDAC4
overlaps with that for CIITA. In agreement with this, HDAC4
competed with CIITA in binding to RFXANK (Fig. 8, C–E) and
inhibited MHCII expression (Figs. 6 and 7).
FIG. 8. Interaction of HDAC4 and HDAC5 with CIITA. A, expression plasmids for HA-HDAC4 and -HDAC5 were transfected into HEK293
cells with an expression plasmid for FLAG-CIITA as specified. Extracts were prepared in buffer B for immunoprecipitation (IP) on M2 agarose, and
bound proteins were eluted with FLAG peptide for Western blotting (WB) analysis with anti-FLAG (upper) or anti-HA (lower) antibody. B, an
expression plasmid for GFP-CIITA was co-transfected into NIH3T3 cells with (upper) or without (lower) an expression plasmid for HA-HDAC5.
24 h post-transfection, cells were fixed and stained with anti-HA antibody to detect HDAC5 by indirect immunofluorescence microscopy. Hoechst
33258 was used to stain DNA for nuclei visualization. C–E, the expression plasmid for HA-RFXANK was transfected into HEK293 cells along with
an expression plasmid for FLAG-RFX5, -RFXAP, or -CIITA. The HA-HDAC4 expression plasmid was also co-transfected as indicated. Extracts
were prepared in buffer K for immunoprecipitation on M2 agarose, and bound proteins were eluted for Western blotting with anti-FLAG (C) or
anti-HA (D) antibody. Western blotting analysis of the extracts with anti-HA antibody is also shown (E). F, schematic about the interaction of
HDAC4 with RFXANK or ANKRA. The domain organization of HDAC4 is depicted as in Fig. 1A. The calmodulin (CaM)-binding motif overlaps with
that for MEF2. The two RFXANK-binding sites (Fig. 3) are indicated with green lines. RFXANK and perhaps also ANKRA bind directly to residues
118–279 (Site 1) but only indirectly to residues 448–666 (Site 2). Although it is unclear how the interaction at Site 1 is inhibited in vivo, residues
146–189 (blue line) act as the autoinhibitory (AI) domain to negatively regulate the interaction of RFXANK at Site 2. It remains to be determined
what mediates this interaction in vivo. The model also applies to the other three class IIa HDACs.
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We also mapped the RFXANK-binding sites on HDAC4. In
vitro binding assays located one binding site to residues 118–
279 of HDAC4 (Fig. 3, A–F). Co-immunoprecipitation revealed
that this site is not functional in vivo, and an indirect binding
site resides within residues 448–666 (Fig. 3, G and H). It is
presently unclear how the indirect interaction is mediated in
vivo (Fig. 8F). One possibility is that a third protein mediates
the binding. Alternatively, a modification event controls the
binding. Intriguingly, an N-terminal region containing resi-
dues 146–189 of HDAC4 negatively regulated the binding (Fig.
3, G and H). In addition, effects of HDAC4 on DRA-Luc reporter
activity were cell line-dependent (Fig. 6 and data not shown).
These results strongly suggest that the interaction of RFXANK
with HDAC4 and its homolog is regulated in vivo (Fig. 8F).
The two RFXANK-binding sites overlap with motifs required
for interaction with MEF2, calmodulin, and 14-3-3 proteins
(Fig. 8F), so an interesting possibility awaiting further inves-
tigation is whether these known partners are involved in the
regulation.
Roles of Class IIa HDACs in Regulating MHCII Expression—
Consistent with their physical interaction with RFXANK and
CIITA, class IIa HDACs repressed CIITA-dependent transcrip-
tion in reporter gene assays (Fig. 6). HDAC4 also inhibited
IFN-inducible gene expression (Fig. 7). These results reinforce
the notion that class IIa HDACs are transcriptional corepres-
sors (6, 8).
How about the underlying repression mechanisms? There are
at least four possibilities. First, mutant 1–666 of HDAC4 was
able to inhibit MHCII expression (Fig. 7B), so this deacetylase
may act through its N-terminal repression domain (8, 55). Sec-
ond, HDAC4 and other class IIa members may mediate histone
deacetylation, which is known to be important for MHCII expres-
sion. Both CIITA and nuclear factor Y interact with p300/CBP
and p300/CBP-associated factor (56, 57). The role of HDACs has
been implicated in the control of MHCII gene expression. The
HDAC inhibitor trichostatin A rescues MHCII expression in tu-
mor cells and mature dendritic cells (58, 59). HDAC1 has been
shown to be recruited by transcription factor YY1 to a cis-acting
element located in the first exon of the HLA-DRA promoter (60).
Moreover, this recruitment leads to repression of inducible HLA-
DRA activation (60). IFN regulates MHCII expression through
CIITA induction. Chromatin immunoprecipitation revealed that
IFN treatment increases CIITA binding to the HLA-DRA pro-
moter and stimulates histone acetylation (61). Conversely, re-
moval of IFN decreases CIITA association with the promoter
and reduces histone acetylation (61). The decrease of histone
acetylation may be due to active deacetylation. Therefore, asso-
ciation of HDAC4 with RFXANK may deacetylate histones to
inhibit MHCII expression.
Third, class IIa HDACs may deacetylate transcription factors
involved. Related to this, the transcriptional activity of CIITA is
known to be up-regulated by acetylation (62, 63). CIITA interacts
with HDAC1 (43) and class IIa HDACs (Fig. 8A), so these en-
zymes may cooperate with each other to deacetylate CIITA and
inhibit transcription. These deacetylases have recently been
shown to regulate the phosphorylation and sumoylation of MEF2
(48). By analogy, they may also modulate the phosphorylation
and sumoylation of CIITA and/or RFX subunits. Finally, the
finding that HDAC4 modestly interfered with the interaction of
RFXANK with RFX5 and CIITA (Fig. 8, C–E) suggests that this
deacetylase and its homologs may hinder enhanceosome assem-
bly. In agreement with this, trichostatin A treatment enhances
the binding of CIITA and RFX5 to MHCII promoters (43). Addi-
tional analyses are needed to distinguish between different pos-
sibilities raised here.
Targeting of CIITA by Class IIa HDACs—The finding that
HDAC4 and HDAC5 interacted with a transcriptional coacti-
vator like CIITA (Fig. 8) is unexpected. One precedent is myo-
cardin, a potent coactivator that was recently shown to interact
with HDAC5 (64). Theoretically, interaction of class IIa HDACs
with coactivators needs to be properly regulated in vivo. Re-
lated to this, these HDACs are subject to regulation by dynamic
nucleocytoplasmic shuttling, and protein kinases, such as
calcium/calmodulin-dependent kinase and protein kinase D
(also known as protein kinase C ), phosphorylate class IIa
HDACs at the 14-3-3 binding sites to promote the cytoplasmic
localization (19–22, 24–27). Our findings thus raise the possi-
bility that protein kinases act through class IIa HDACs to
modulate IFN signaling. Of note, CIITA has also been shown
to mediate transcriptional repression (33, 65), so it may recruit
these HDACs to inhibit transcription. CIITA is a member of the
nucleotide-binding oligomorization domain/caterpiller family
(66, 67), so it will be interesting to determine whether class IIa
HDACs also target other members of this important family.
Conclusions—The results presented herein demonstrate
that class IIa HDACs interact with both ANKRA and RFXANK
through their ankyrin repeats. Importantly, the interaction is
regulated in vivo (Fig. 8F). Another group has independently
identified RFXANK as a binding partner of HDAC5 in yeast
two-hybrid screens.2 Our results also show that by targeting
RFXANK and CIITA, HDAC4 inhibits MHCII expression. Se-
quence homology to RFXANK and association with class IIa
HDACs suggest that ANKRA may play a role in transcriptional
control. Therefore, ANKRA, RFXANK, and CIITA are novel
targets of class IIa HDACs.
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